Aug. 28 at 7:54 PM
$BFRI I looked at the data for their other trials, and wow. The phase 3 data they got for the other trial AMELUZ® Actinic Keratosis: Trunk & Extremities, is good too, and they plan to submit that one next month (late Q3 2026). Therefore, we have two catalysts coming up next month. Then breakeven for the end of the year too. Plus the warrants of BFRIW will be gone come Oct. If they can get around that XL lamp patent too, it will be looking good for them. We just need each catalyst to hit, and this can hit the 9/share analyst number by year-end going into next year, if not more like 12/share. I like what I see, and the price is looking so discounted it isn't even funny. Of course, everything has to hit perfectly.
